ADM2 Linked to Cancer Invasion and Metastasis

A study published in Oncogene on October 10, 2026, identifies adrenomedullin 2 (ADM2), a peptide hormone, as a regulator of cancer-cell invasion and metastasis in experimental models. The researchers observed ADM2-producing cancer cells moving toward and entering blood vessels, a process called intravasation. ^[1]

When researchers reduced ADM2 expression, they observed less invasion and intravasation, as well as fewer or smaller metastatic lesions in chicken-embryo and mouse models; similar effects were reported in tested human cancer cell lines. ^[1] These results point to ADM2 as a potential research target, not an established treatment: the study does not show that targeting ADM2 is effective or safe in people. ^[1]